StockNews.com started coverage on shares of Organovo (NASDAQ:ONVO – Free Report) in a research note issued to investors on Thursday morning. The firm issued a sell rating on the medical research company’s stock.
Organovo Price Performance
Shares of NASDAQ:ONVO opened at $0.57 on Thursday. The company’s fifty day moving average price is $0.69 and its 200-day moving average price is $0.90. The firm has a market capitalization of $8.13 million, a price-to-earnings ratio of -0.35 and a beta of 0.68. Organovo has a one year low of $0.50 and a one year high of $2.05.
Organovo (NASDAQ:ONVO – Get Free Report) last posted its earnings results on Friday, May 31st. The medical research company reported ($0.29) EPS for the quarter, topping the consensus estimate of ($0.42) by $0.13. The company had revenue of $0.03 million during the quarter, compared to analysts’ expectations of $0.08 million. As a group, equities research analysts expect that Organovo will post -0.96 EPS for the current year.
Institutional Trading of Organovo
Organovo Company Profile
Organovo Holdings, Inc, a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture.
Read More
- Five stocks we like better than Organovo
- How to Calculate Retirement Income: MarketBeat’s Calculator
- Bumble’s Valuation Hits an All-Time Low, Can Its Fortunes Change?
- Stock Trading Terms – Stock Terms Every Investor Needs to Know
- MarketBeat Week in Review – 8/12 – 8/16
- 3 REITs to Buy and Hold for the Long Term
- JD.com Earnings Surprise: China’s Outlook Better Than Expected
Receive News & Ratings for Organovo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Organovo and related companies with MarketBeat.com's FREE daily email newsletter.